369 results on '"Macconaill, Laura E."'
Search Results
2. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer
3. Author Correction: An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
4. Twists and Turns from 'Tumor in Tumor' Profiling: Surveillance of CLL leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis
5. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
6. MatchMiner: an open-source platform for cancer precision medicine
7. Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma
8. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.
9. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032
10. Supplementary Figures 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
11. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium
12. Table S3 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
13. Supplementary Appendix from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
14. Data from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
15. Supplemental Methods, Supplemental Tables 1-2, Supplemental Figures 1-4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
16. Supplemental File 1 from AACR Project GENIE: Powering Precision Medicine through an International Consortium
17. Supplementary Methods, Tables 1-9, Figure Legends 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
18. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA
19. Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma
20. eFigure1 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
21. Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
22. Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
23. Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
24. Supplementary Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
25. Supplementary Methods and Results from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
26. Supplementary Figures from Genomic Characterization of de novo Metastatic Breast Cancer
27. Supplementary File 3 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
28. Supplementary File 2 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
29. Supplementary File 1 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
30. Supplementary File 5 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
31. Supplementary File 4 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
32. Supplementary File 6 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
33. Materials and Methods, Legends, Tables and Figures from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
34. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas
35. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
36. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
37. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
38. Integrated Clinico-Genomic Analysis of Genetic Ancestry in 1,614 Patients With Cancer Treated With Immune Checkpoint Inhibitors
39. MEK1 Mutations Confer Resistance to MEK and B-RAF Inhibition
40. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
41. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study
42. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung
43. Brave-ish New World—What’s Needed to Make Precision Oncology a Practical Reality
44. Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment
45. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women
46. Novel Genetic Mutations in a Sporadic Port-Wine Stain
47. Twists and turns from “tumor in tumor” profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis
48. Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.
49. Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.
50. An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.